This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

​iNova Pharmaceutical's acquisition of Juno PC set to receive Australian regulatory scrutiny

( September 2, 2019, 00:45 GMT | Official Statement) -- MLex Summary: The proposed acquisition of Australian pharmaceutical joint venture Juno PC by iNova Pharmaceuticals (Australia) will be reviewed by the country’s competition regulator. In a market inquiries letter released today, the Australian Competition & Consumer Commission said it would focus its probe on whether, and to what extent, iNova and Juno PC’s products are likely to compete and whether a generic phentermine hydrochloride product is likely to commence supply in Australia. The drug is central to the regulator’s considerations, because Juno PC is a special-purpose joint venture seeking to develop, register, manufacture, license and supply a patent-protected phentermine hydrochloride product in tablet form. The ACCC has set Oct. 31 as the tentative date for a decision.The ACCC's market-inquiries letter is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections